Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly to $1,083 from $1,023 and keeps an Overweight rating on the shares. The firm tweaked its Mounjaro/Zepbound estimates in 2024 and raised outer year Zepbound estimates on refreshed pricing assumptions given recent management commentary, the analyst tells investors in a Q2 earnings preview note for the Biopharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly CFO Anat Ashkenazi Resigns, Gordon Brooks Steps In
- Eli Lilly price target raised to $1,025 from $913 at Barclays
- Novo Nordisk (NYSE:NVO) Shares Dip After JAMA Study Results
- Patients more likely to lose weight with Mounjaro than Ozempic, study says
- Morphic downgraded to Market Perform from Outperform at BMO Capital